UPDATE 1-Amgen melanoma drug fails to improve overall survival rates
April 04, 2014 at 11:33 AM EDT
April 4 (Reuters) - Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.
